Evidence map›Paper›PMID 36747264›Full record

ArticleBMC veterinary research2023

Palmitoyl-glucosamine co-micronized with curcumin for maintenance of meloxicam-induced pain relief in dogs with osteoarthritis pain.

Giorgia Della Rocca, Carlo Schievano, Alessandra Di Salvo, Maria Beatrice Conti, Maria Federica Della Valle

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Turmeric and Curcumin-Health-Promoting Properties in Humans versus Dogs.International journal of molecular sciences · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Giorgia Della RoccaDepartment of Veterinary Medicine, Centro Di Ricerca Sul Dolore Animale (CeRiDA), Università Degli Studi Di Perugia, 06123, Perugia, Italy. giorgia.dellarocca@unipg.it.
Carlo SchievanoInnovative Statistical Research SRL, Prato Della Valle 24, 35123, Padua, Italy.
Alessandra Di SalvoDepartment of Veterinary Medicine, Centro Di Ricerca Sul Dolore Animale (CeRiDA), Università Degli Studi Di Perugia, 06123, Perugia, Italy.
Maria Beatrice ContiDepartment of Veterinary Medicine, Centro Di Ricerca Sul Dolore Animale (CeRiDA), Università Degli Studi Di Perugia, 06123, Perugia, Italy.
Maria Federica Della ValleCeDIS (Centro di Documentazione e Informazione Scientifica), Innovet Italia SRL, Via Leonardo da Vinci 3, 35030, Saccolongo, Italy.
University of Perugia · ITIstituto Nazionale di Documentazione Innovazione e Ricerca Educativa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteoarthritis (OA) pain is the number one cause of chronic pain in dogs. Multimodal treatment, including combining safe and effective nutritional interventions with non-steroidal anti-inflammatory drugs (NSAIDs), is currently considered one of the most appropriate choices for managing OA pain. Palmitoyl-glucosamine is a feed material belonging to the ALIAmide family, whose parent molecule is the prohomeostatic lipid amide N-palmitoyl-ethanolamine. Curcumin is a promising plant antioxidant. The present study aimed at investigating whether 18-week dietary integration with palmitoyl-glucosamine co-micronized with curcumin was able to maintain pain relief in dogs with OA-associated chronic pain receiving meloxicam (1.5 mg/ml oral suspension) on a tapering regimen (progressive 25% decrease of the original 0.1 mg/kg/day dose, on a biweekly basis) during the first 8 weeks of treatment. Pain was assessed both by the owners and veterinary surgeons, with the first using both subjective evaluation and validated metrology instruments-i.e., Helsinki Chronic Pain Index (HCPI) and Canine Brief Pain Inventory (CBPI)-while the second rating the severity of lameness and pain on palpation on two previously used 5-point scales.

resultsA total of fifty-eight dogs with OA chronic pain entered the uncontrolled study. Pain on HCPI was considered severe at baseline (range 18-39). Based on owner's assessment, 90% of dogs who responded to meloxicam at the full-dose regimen could reduce meloxicam up to 25% of the original dose without experiencing pain worsening. Moreover, 75% of dogs was assessed as having no pain increase ten weeks after meloxicam withdrawal. A statistically significant decrease of pain severity as scored by HCPI (P < 0.0001) was observed two and ten weeks after meloxicam withdrawal compared to study entry (17.0 ± 1.05 and 15.1 ± 1.02, respectively, vs 29.0 ± 0.74; mean ± SEM). After meloxicam withdrawal, no statistically significant change in the CBPI scores was recorded. Pain on palpation and lameness significantly changed to less severe distributions along the study period (P < 0.0001).

conclusionThe findings appear to suggest that dietary integration with palmitoyl-glucosamine co-micronized with curcumin was able to maintain meloxicam-induced pain relief in dogs with severe OA chronic pain.

Indexed as

Chronic PainCurcuminDog DiseasesOsteoarthritisAnimalsAnti-Inflammatory Agents, Non-SteroidalDogsGlucosamineLameness, AnimalMeloxicamAnti-Inflammatory Agents, Non-SteroidalCurcuminGlucosamineMeloxicamALIAmideChronic painCurcuminDogsMeloxicamMultimodal analgesiaNon-steroidal anti-inflammatory drugsOsteoarthritisPalmitoyl-glucosamine

Identifiers

PMID36747264
PMCPMC9903516
OpenAlexW4319332939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.